Page 10«..9101112..2030..»

Category : Human Longevity

6 Longevity-Promoting Herbs and Spices To Add to Your Cooking Rotation – Well+Good

The term longevity refers to the number of years you live, and it does have a limit. Our bodies are not designed to live to 120 years, although many of us would like to live that long if we had quality of life for that long, says Gary W. Small, MD, the physician in chief for behavioral health at Hackensack Meridian Health in New Jersey and the former director of the UCLA Longevity Center.

In reality, the normal (and inevitable) processes of oxidative stress and inflammation are thought to contribute to our gradual decline in health as we get older. That doesnt mean were helpless when it comes to our health. In fact, the foods we eat every day play a major role in healthy aging and longevityand a few herbs and spices may be especially helpful.

Inflammation is a natural part of the immune response to fight infection and repair damage from injuries. Excess inflammationis associated with chronic diseases including cardiovascular disease, cancer, diabetes, kidney disease, and non-alcoholic fatty liver disease. We know that heightened inflammation and oxidative stress contribute to age-related diseases, says Dr. Small. If you look at a lot of studies and blood markers of inflammation, we find that age itself is often associated with heightened inflammation. Lifestyle habits, including poor diet, lack of exercise, stress, and a shortage of quality sleep play an important role in accelerating inflammation, he adds.

Thats where plant-based foods can come in. Plants naturally have anti-inflammatory and antioxidant properties, which Dr. Small says may play some role in healthy aging and longevity. This may slow down the process of aging as well as support the immune system and protect against chronic conditions that are more common with age, explains Rachelle Robinette, a clinical herbalist and holistic health practitioner (and host of Well+Goods YouTube show, Plant Based). While we dont know for sure exactly how many antioxidants we need to consume for these effects, studies show that people who consume these kinds of foods live longer and better, says Dr. Small.

That doesnt prove that consuming any one particular food or supplement will have enough of an effect on your inflammation levels to actually have an impact on disease, Dr. Small adds. Were always looking for a quick fix or magic bulletEveryone wants a remedy, but none can even work well if diet and lifestyle are not in place, adds Robinette. In terms of longevity, diet and lifestyle are going to matter more than any herb or supplement. Herbs work wonderfully as medicine, but they really are supplemental.

Caveats aside, some foods really do boast more concentrated levels of disease- and age-fighting compounds than othersand that certainly cant hurt in moderation when you integrate them into your cooking routine. Whats great about spices is it makes your diet more palatable, you want a diet thats nutritious but delicious, says Dr. Small. (Just remember: You should always talk to your doctor before starting any new supplement; some can be toxic at higher doses, especially if youre taking certain prescription medications.)

Ginger is the epitome of food medicine, as Robinette calls it. The compound gingerol in ginger is the source of most of the plants many benefits; it has powerful anti-inflammatory and antioxidant effects and may have anti-cancer properties. (Which, hello longevity!) The Mayo Clinic is currently investigating whether eating 2,000 mg of ginger a day for six weeks can boost the microbiome, aka the collection of bacteria, fungi, and viruses that make up a large part of the human body. That would be a big deal, Robinette explains, since your microbiome affects your overall health, including your brain, mood, and immune system.

Robinette recommends having ginger a few times a week as a fresh extract, grated into food, added to stir-fries, or sliced in a hot cup of tea. You can also try Robinettes recipe for ginger shotswhich may be especially helpful during cold and flu season. I do several shots per day in winter, she says.

Heres the step-by-step for making Robeinettes ginger shot to reap the benefits of the plant:

You cant talk about herbs for longevity without talking about turmeric. Another powerful antioxidant and anti-inflammatory spice, turmeric is where curry gets its flavorand the antioxidant compound curcumin. In 2018, Dr. Small authored a small double-blind studyshowing that taking two 90 mg curcumin supplements daily for 18 months improved memory and attention in older adults with mild memory problems. We did find it has a significant effectcompared to placebo, says Dr. Small, who is currently expanding the research to a much larger sample size across the U.S. While hes not sure exactly how curcumin works to boost brain health, my best guess is its the reduction in inflammation, he says.

Robinette points out that turmeric has been called a natural immunomodulator, or a substance that helps keep the immune system in check by boosting immunity when you need it and tamping it down to prevent excess inflammation involved in many chronic conditions. Some research suggests that turmeric could potentially even play a role in preventing and treating cancer, cardiovascular disease, metabolic conditions, neurological disease, and skin diseases.

Although it certainly doesnt hurt to enjoy more foods with turmeric, youll need to pop a curcumin supplement to get the full health benefits of the spice. For therapeutic purposes, you want to take higher doses, says Robinette. Try to take the supplement when you eat your meals, preferably with fat (like fatty fish or nuts) to increase the bioavailability of curcumin. (Just check with your doctor before you start supplementing to ensure it doesnt interact with any health conditions you have or medications you take.)

Heres even more intel on all the benefits of turmeric:

Spirulina is a type of cyanobacteria (or algae) thats grown in water and sold as tablets or in powder form. It contains a high amount of protein for a plant. And with loads of vitamins, including iron, potassium, zinc, calcium, and B vitamins, its almost identical, nutritionally, to mothers milk, Robinette adds.

Given that following a plant-forward diet is key to healthy aging, Robinette says supplementing with spirulina can be beneficial for healthy aging. Nobody eats enough plants. Supplementing with something thats really concentrated like spirulina is acheat way to get more greens. Just be sure to check your spirulina comes from a clean water source. Aim for a teaspoon per day, says Robinette; since spirulina has a seaweed-esque flavor, she suggests tossing it into pesto or any savory recipe with greens, like salad dressings, soups, or dips.

Jalapenos, cayenne, and other types of peppers contain capsaicin, a chemical compound that makes food spicy and has antioxidant and anti-inflammatory properties. Dr. Small points to a 2015 observational study of nearly half a million people in China, which concluded that people who ate more spicy foods were less likely to die of all causesand specifically of cancer, heart disease, and respiratory diseasesthan people who didnt or rarely ate these foods. The authors concluded the effect may be due to capsaicin.

How often should you hit the hot sauce? The Chinese researchers found that the benefits of capsaicin were cumulative; people who ate spicy foods six or seven times per week were least likely to die of any cause. But eating spicy meals even a couple of times a week seemed to have some benefit.

There are only a couple dozen plant adaptogens, including ginseng, that help increase the bodys resilience to stressors of all kinds. While you might associate ginseng with Traditional Chinese Medicine, its one of the oldest medicinal herbs used all over the world to support human health, Robinette says.

Robinson explains that adaptogens like ginseng micro-trigger the body, so it gets stronger over time to physical, emotional, and environmental stressors (like light and sounds). Its not impervious to stress, but youre better able to recover and not overreact, she says. Its helping move you between the sympathetic and parasympathetic states with more ease. Many of us are dealing with some level of stress these days, which can, over time, suppress the immune system and even shorten your lifespan by contributing to inflammation in the gut and disrupting sleep. Chronic stress is counterproductive for longevity in many ways, says Robinette.

Like most herbs, ginseng has antioxidant anti-inflammatory properties, says Robinette. A wealth of research suggests ginseng may have immunomodulatory and anti-cancer properties, and that it may even help control blood sugar in people with diabetes and improve learning and memory. Unlike most of the other herbs and spices on this list, you really need to take ginseng every day for an extended period of time to see benefits, says Robinette. You can enjoy it in any form, including tea, powder, capsule, and tincturejust be sure to talk to your doctor first, as ginseng can interact with some drugs (like warfarin and insulin).

The powerful phytochemicals, or plant antioxidants, in blueberries helps clean up free radicals, fighting the effects of inflammation that can in turn impact your health and longetivity. There are studies showing antioxidant foods like blueberries or pomegranatesshow moderate effects [on oxidative stress], though not as consistent or as big of an effect as we saw with curcumin, says Dr. Small. While were waiting to support this science, it certainly makes sense to try to consume colorful fresh fruits and veggies.

Wild blueberries, in particular, tend to be highest in gut-boosting fiber and antioxidants, says Robinette: They have more skin than grocery store blueberries (which are still good for you but bred to be sweet). Eat them fresh, sprinkle blueberry powder into your smoothies and cereal, or spread blueberry (or any other superfruit) paste onto toast like thick jam.

Oh hi! You look like someone who loves free workouts, discounts for cult-fave wellness brands, and exclusive Well+Good content. Sign up for Well+, our online community of wellness insiders, and unlock your rewards instantly.

Read more here:
6 Longevity-Promoting Herbs and Spices To Add to Your Cooking Rotation - Well+Good

Recommendation and review posted by Alexandra Lee Anderson

Global Stoma/Ostomy Care Market Trajectory & Analytics Report 2020: Focus on Stoma Quality of Life Paves Way for Increased Spending on…

DUBLIN--(BUSINESS WIRE)--The "Stoma/Ostomy Care - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Focus on Stoma Quality of Life Paves Way for Increased Spending on Stoma/Ostomy Care Products. Market to Reach $3.8 Billion

The global market for Stoma/Ostomy Care is projected to reach US$3.8 billion by the year 2027, trailing a post COVID-19 CAGR of 4.2% over the analysis period 2020 through 2027.

The growth will be driven by rapidly aging population increase in the number of operative procedures involving creation of intestinal stoma and the resulting focus shed on stoma quality of life. World's population is rapidly aging supported by the increase in longevity as modern medicine becomes increasingly effective in preventing chronic disease, and reducing mortality. Also, easy access to age-friendly primary healthcare and growing sophistication of healthcare infrastructure play key roles in longevity.

For the first time in human history the percentage of older people in the total population is continuing to increase. In addition to the aforementioned increase in life expectancy, falling fertility rates are accelerating the trend. The aging population creates massive challenges for the healthcare system since it means larger chronic disease burden.

Among the many diseases of the elderly such as dementia; arthritis; blindness; chronic bronchitis; motor neurone diseases; osteoporosis; Parkinson's disease; stroke; CKD; and Alzheimer's, incontinence and bowel obstruction caused by colorectal cancer and other diseases that require surgical removal parts of the rectum, anus and colon requires the highest nurse care and self-care management needs. Colorectal cancer is the leading cause for creation of stomas/ostomy accounting for 45.6% of the prevalence rate. Juxtaposed with this fact, the high prevalence of colorectal cancer, over 60% of the incidence rate, among the elderly aged over 70+ makes aging population a powerful demographic growth driver for stoma/ostomy care products.

Colostomy is the most popular type of procedure performed on 45.2% of ostomy patients in the 60+ age group, while Ileostomy is the second most common procedure performed on people aged over 60 with over 38.7% of ostomy patients in the 60+ age group having Ileostomy. Urostomy is performed on 16.1% of ostomy patients in the 60+ age group. The ostomy market also benefits from the increasing survival rates from colorectal and bladder cancer. Mortality rate from these cancers has improved considerably during the past decades, both for women and for men. Resultantly, the increasing life expectancy of people bodes well for the ostomy care products market, considering the chronic nature of the conditions and the increasing need to use ostomy products. The annual ostomy product costs per patient are estimated in the range of US$1,000 to US$1,200 on an on average globally.

Prices of ostomy products remain stable due to fixed reimbursement levels. Caring for stoma is extremely important given the high risk and financial burden of complications following ostomy surgery. Lack of proper ostomy care is the leading cause for hospital readmission rates and ER visits in the United States second to kidney transplants. Over the years, rising awareness and improving standards of ostomy care have helped drive the market for stoma/ostomy care products.

The field of stoma care is also evolving and improving with stoma care emerging into a unique field in nursing. Popularity and easy availability of specially qualified stoma care nurses; development of best practice guidelines; easy access to new clinical insights and tools are all helping to deliver the best possible care for stoma patients.

Among the noteworthy trends in the global market for ostomy bags has been the increasing tender based and bulk purchases of the bags by large hospitals and healthcare facilities with huge number of inpatients on whom ostomies have been performed and also patients with fresh stomas. In order to maintain uninterrupted supply of these bags for better ostomy care for inpatients, healthcare facilities have been following the tender-based procurement of the bags.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/4d7qea

Read more:
Global Stoma/Ostomy Care Market Trajectory & Analytics Report 2020: Focus on Stoma Quality of Life Paves Way for Increased Spending on...

Recommendation and review posted by Alexandra Lee Anderson

Leading Healthy Aging Researcher Brian Kennedy, Ph.D., To Address Natural Health Industry On Impact Of Nutrition On Biological Age – PRNewswire

FERNANDINA BEACH, Fla., Dec. 9, 2020 /PRNewswire/ -- Ponce De Leon Health, Inc. ("Ponce de Leon"), a longevity research company focused on the reversal of epigenetic aging, announced today that Brian Kennedy, Ph.D., will speak at the SupplySide Network "Healthy Aging Never Gets Old" event on December 10th, 2020, at 1:00 PM Eastern.Doctor Kennedy is currently serving as Director of the Centre for Healthy Longevity, at the National University of Singapore.Registration for this free event can be found on theSupplySide Network 365platform.

Doctor Kennedy was invited to address industry leaders to discuss recent research which led to the development of Rejuvant LifeTabs, a dietary supplement designed for healthier aging. Informa Health & Nutrition named Rejuvant LifeTabs asthe top Consumer Packaged Goods winner in the Best Life-Span Specificcategory, at the 2020 NEXTY SupplySide Awards. According to Informa, Rejuvant contains "a ground-breaking ingredientLifeAKGand a meticulously researched, time-release formula tailored to men and women."

This news follows on the heels of Ponce De Leon Health announcement in September with the first peer-reviewed study of a non-drug substance demonstrating improvements in mammalian lifespan, reduction in frailty, and reduction in time of suffering. The results of the research were published in the September 1, 2020 issue of the journal Cell Metabolism. The researchers found that LifeAKG "promotes longer, healthier life associated with a decrease in levels of inflammatory cytokines. Strikingly, the reduction in frailty led the scientists to "propose that Ca-AKG compresses the period of morbidity." The publication, titled "Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice," and was authored by Azar Shamirzadi, Ph.D., et al., and directly led to the development of Rejuvant LifeTabs.

Tom Weldon, the CEO and Founder of Ponce De Leon Health, remarked, "We're very proud of our research, past and ongoing, and committed to reversing epigenetic aging. Our product, Rejuvant LifeTabs, is emblematic of the growing discoveries in the field of epigenetics, or the changes made by modification of gene expression.We continue to conduct new human and animal trials to better demonstrate the benefits of Rejuvant on biological aging, healthspan and lifespan."

Todd Runestad, Senior Editor of Ingredients and Supplements, New Hope Media and Natural Products Insider, invited Dr. Kennedy to speak at the event.Said Mr. Runestad, "healthy aging is a prime consideration of supplement usersfrom specific health conditions like bone or joint or cognitive health, to the more general concept of aging gracefully. Of course, people have long sought out skin-health products, but the new frontier is the provocative research around epigenetics and nutrigenomicsthat one's lifespan is not just predicated on genetics, but that gene expression can be modulated by diet and specific dietary supplements."

Mr. Runestad added, "Brian Kennedy has been researching such concepts for decades now. He is one of the world's leading anti-aging researchers, and he may have come up with this decade's resveratrolthe fountain of youth molecule found in red wine. We awarded a NEXTY award for the year's best innovation, integrity and inspiration, to a supplement brand Dr. Kennedy helped develop for Ponce de Leon Health. The company's Rejuvant LifeTabs, coupled with an in-home genetic test kit, allows consumers the ability to actually track over time genetic markers of aging while taking the supplement. Personalized health care meets anti-aging science."

About Ponce De Leon HealthPonce De Leon Health (www.PDLHealth.com) is a commercial-stage longevity company focused on the discovery, development and commercialization of non-prescription consumer products to address the reversal of epigenetic aging. Their goal is to increase human healthspan, improve quality of life, and reduce the cost of providing late stage health care to customers.

To learn more about the groundbreaking science behind Rejuvant LifeTabsvisit http://www.rejuvant.com or follow @rejuvanthealth(Facebook), @Rejuvant (Twitter), or Ponce De Leon Health (YouTube).

SOURCE Ponce De Leon Health

http://pdlhealth.com

Go here to see the original:
Leading Healthy Aging Researcher Brian Kennedy, Ph.D., To Address Natural Health Industry On Impact Of Nutrition On Biological Age - PRNewswire

Recommendation and review posted by Alexandra Lee Anderson

Biopharma Money on the Move: December 2 – 8 – BioSpace

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies.

Forbion

European venture capital firmForbionrounded up$545 millionfor its fifthlife sciences fund. Investments will be made in about 15 therapeutics companies, with a third created byForbionthrough its Build opportunities. The rest will be invested in highly impactful existing companies.With offices in the Netherlands, Germany and Singapore, theplan is to invest about 80% into Europeancompanies and the rest in North American startups.

AbCellera

Since partnering with Eli Lilly to produce the first monoclonal antibody therapyapprovedfor mild-to-moderate COVID-19 patients,antibody discovery companyAbCellerais going big on the Nasdaq. Offering 23 million shares between $14-$17 apiecefor a hopeful total of$391 million, the company is lining up the biggest debut on record for a Canadian biotech.AbCellerasAI-powered antibody discovery platform speeds theotherwise lengthy and gruelingprocessby analyzing the database of natural immune systems to findantibodies that canbe developed into drugs.Thepromiseto partners is to move quickly. Reduce cost. Tackle the toughest problems in drug development. Investors include big names like Peter Thiel, Bill and Melinda Gates Foundation and more.

Silverback Therapeutics

Silverback goes for gold, upping its IPO for a4thtimesince the initial announcement. Originally slated for $125 million,the biotech is now shooting for a$241 millionraise by offering 11.5 million shares at $21 each. Some of the funds will be used for thedevelopment of therapeutics for oncology and other serious diseases through its proprietaryImmunoTACtechnology platform.TheImmunoTACplatform pairs proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Silverbacks lead candidate is currently in a Phase I trial in adults with HER2-expressing solid tumors.

Nuance Pharma

Theres nothing subtle about Nuances$181 millionSeries D financing round. The fully integrated pharmaceutical company creates value through Chinas specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory.Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets.

SigilonTherapeutics

Now live on the ticker,Sigilonhopes to sell 7 million shares fora$126 millionraise.Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases. The companysproduct candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected bySigilonsAfibromer biomaterials matrix, which shields them from immune rejection and fibrosis. In March, the company closed an $80.3 million Series B.

RayzeBio

Launched in October with a$45 million Series A,RayzeBioput a Series B on their Christmas list and Santa came early.With a pipeline of targeted radiopharmaceuticals against validated solid tumors, the biotech looks toutilizethe$105 millionraise into advancing their programs toward the clinic.Thecompanys goal is focused on improving outcomes for cancer patients by harnessing the power of targeted radioisotopes.RayzeBiois alsofunneling cash intoexpandingits HQ in San Diego with plans to further develop internal R&D.

SciNeuroPharmaceuticals

Cornering the untapped Chinese CNS market,SciNeurolaunched with$100 millionin their pocket. Headquartered in Shanghai, the company will also have a hub in Philadelphia.CEO and founder Min Li knows a thing or two from his time running GSKs neuro R&D group before the company shuttered the program in 2017.Li stated, One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. The impact of CNS diseases extends beyond patientsto their families and society as well. Theassumption isSciNeurowill start with Parkinsons diseaseand painin addition to rare genetic diseases, after scaling up staffing.

BioAge

Looking to extend the humanhealthspan,BioAgeraised$90 millionin an oversubscribed Series C. The companyis at the forefront of understanding the biological drivers of aging with its unique and cutting-edge systems biology platform. A supporting pipeline has medicines to target these key pathways to reverse or eradicate disease and extend the years of healthy life remaining.BioAgeis on the cusp of takingpilot therapies BGE-117 and BGE-175 into clinical trials, targetingthe first half of 2021.According to a press release, proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increasehealthspanand lifespan, augmentBioAgesartificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.

Remix Therapeutics

Laying down a new track for RNA processing, Remix launched with$81 millionin financing. Funds will be used to support development of theREMastertechnology platform and advance the companys pipeline of RNA processing targeted therapeutics as well.As we reach the limits of what is easily druggable with protein targeting therapies, reprogramming RNA processing represents an exciting new therapeutic opportunity. We believe we can precisely target the cellular complexes that process RNA to address the underlying drivers of disease, working upstream of protein expression, said Pete Smith, Ph.D., co-founder, president and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence.

Pear Therapeutics

Pear picked a sweet dealthis weekwith an$80 millionseries D backed by Temasek, 5am Ventures, Novartis andquite a fewmore.Combining biology and technology, the company specializes in Prescription Digital Therapeutics (PDTs),a new therapeutic class that treats serious disease alone or with drugs using software. PearsreSET,reSET-OandSomrystare the first PDTs to receive FDA approval for treating disease. The products are used to treat substanceuse disorder,opioid use disordersand chronic insomnia, respectively. Series D funds will be used to acceleratereimbursementcoveragefor its three commercial products.

Noema Pharma

Co-founded by the former VP of neuroscience for Roche, Noema Pharma raised$59 millionin a Series A round. With an intent to develop treatment for rare neurological disease whereexisting therapies have not shown much success, the company has licensed four clinical stage assets from Roche. The Roche-assets are aimed at seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourettesyndrome and other rare neurologicaldisorders.Already having been in clinical studies at Roche, all four candidates have strong clinical and preclinical safety packages. Thisshouldallow Noemato quickly pursue a series of clinical programs in orphan central nervous system (CNS) indications.

Most read today on BioSpace:

View post:
Biopharma Money on the Move: December 2 - 8 - BioSpace

Recommendation and review posted by Alexandra Lee Anderson

Warm Up Your Content Strategy with a Human Touch – The Content Standard by Skyword

Content strategy pivots have been a normal response in the wake of COVID-19. As physical marketing spend shifts to digital channels, brands are looking to sales enablement and demand generation. But theres another, more subtle shift underway in the B2B world. Brands have begun embracing more of a human touchand in some cases, a conversational tonein their content strategies. Here are some emerging examples that can help point the way toward a new approach to your brand voice and communications.

How have your brands communications evolved in response to COVID-19? If your answer is not much, it may be time to reassess. During a recent visit to the Harvard Business Review, I used up my free allotment of articles. A banner ad invited me to log in or subscribe with a pithy headline: We hate paywalls too.

It was such a sharp, incisive take on the common complaints B2B readers haveand yet it caught my attention for the fun tone as well.

What does a banner ad have to do with communicating in 2021 and beyond? The world has undergone a seismic shifta fact thats leading many brands to reassess how theyre communicating. As the Harvard Business Review (HBR) notes, presenting with empathy and transparency is key. That can mean moving away from traditional messaging and finding a more authentic take on the situation unfolding.

The nuances of brand voice are more delicate than ever, says HBR. Brands that use this time to be commercially exploitative will not fare well. Better to do as Guinness did in the period surrounding St. Patricks Day, when the company shifted its focus away from celebrations and pub gatherings and instead leaned into a message of longevity and wellbeing. In these moments, we dont have all the answers, and we need to acknowledge that. If you make pledges, even during uncertain times, you have to be able to deliver on what you say.

If youre looking for creative strategies to take your B2B brand to a new level, consider these approaches.

Adding a human touch to content strategies runs the gamut from very simple to complex. Take a moment to consider how your buyers experience may have changed. Theyve traded busy days in the office and long commutes for endless Zoom calls, working while educating home-schooled children, and navigating a world that is more logistically complex than it was a year ago. Simple, straightforward communication eliminates barriers and helps people find the information they need quickly and efficiently.

The Marketing Insider Group recommends three basic tactics that serve marketers well in any B2B communication:

Just taking these initial steps will help ensure that what you create is clear, easy to digest, and capable of delivering real value.

Brands struggle to forge meaningful connections when they only create generic content that doesnt address their consumers realities. As Forbes notes, several brands in the B2B world have taken the opportunity to deliver what customers needed. Consider shipping, which was suddenly upended by increased demand, illness-related employee shortages, product out-of-stocks, and much more.

Forbes offered up the example of FedEx, which created clear, concise, and relevant communications for customers: Shipping was thrown into disarray with COVID, and many supply chains are still adjusting. FedEx, known for being one of the most trusted B2B companies, created numerous resources for small business owners, including templates for COVID signage, shipping discounts and expert advice and best practices. The company moved beyond just shipping to provide resources and guidance for the many new challenges small businesses face.

With physical sales and marketing opportunities like industry events and trade shows put on hold, partner networks are pushing for revitalization. One of the most important services that companies deliver to partners is crafting clear, concise marketing campaigns that drive demand with their audiences. In the past few months, that work has trended toward simple and streamlined campaigns.

Some now-emerging trends include:

As McKinsey notes, building capabilities for turbulent times not only helps you not only thrive, but it helps you pivot when unexpected changes arise. The authors note that maintaining a strong customer experience in crisis requires rapid research to understand changing dynamics and new pain points as well as agile innovation to address them. In a digital-led world, brand voice plays an important role in winning and retaining customers.

Recently, I worked with a customer to select a newsletter provider. The list included top brands across the newsletter industry. But after a frustrating demo with a sales rep and challenges navigating different complex web pages, the client chose Mailchimp. Its a good service, but not necessarily the one I expected them to select. When the CMO shared her rationale, it made sense. I could immediately understand everything they did and offered. The language was simple and easy to navigate.

Building your brand voice can help you reach frustrated, busy B2B buyers who need solutions to urgent problemsand who have less time, patience, and other resources to wade through reams of jargon-laden copy to find what they need. Mailchimp, by simple virtue of the brands clear, clean, and accessible content strategy, won a customer whos now singing their praises and sending along other busy executives in search of digital solutions they can implement and scale quickly. Investing in your brand voice is a capability that can grow and streamline business performance in unexpected ways.

Finding your voice through the end of 2020 and planning ahead into 2021 raises an important question for brand marketers: Does your content strategy have a human touch? Dont forget that your buyer has a completely different set of needs, expectations, and business realities than when you crafted last years content strategy. Add a human touchwith humor, clarity, and real talkto stand out and build connections that draw prospective buyers into your sales funnel.

Eager for more insights like this? Sign up for The Content Standard today.

Featured image by Andy Art on Unsplash.

Visit link:
Warm Up Your Content Strategy with a Human Touch - The Content Standard by Skyword

Recommendation and review posted by Alexandra Lee Anderson

Bestselling Author, Jill Wright, Celebrates Feature in Thriving Women Magazine With Presale of Codes of Longevity – Press Release – Digital Journal

Denver, CO, USA - December 11, 2020 - Author and CEO Jill Wright is celebrating more than the holidays this month. The bestselling author is featured in this month's issue of Thriving Women Magazine. The December issue is dedicated to longevity. Wright says that she is honored to have been selected to share her favorite ways to end 2020 in optimal health for an incredible new year to come.

"Living a long life well to enjoy this holiday season and many more begins in this moment now," explains Wright. "Small steps, little actions, done over time amplify to create your long and thriving life." Because of this, Wright is celebrating her feature by releasing her Codes of Longevity on Kindle Presale for 99 cents.

Codes of Longevity is packed full of practical and tactical solutions. This book is the bridge between science and the soul. Connecting the dots between lifespan, healthspan, and wellspan through epigenetics reveals how the pieces of a long life lived well all fit together for one's personalized longevity blueprint. Readers will learn how to achieve the most powerful age-defying results beginning today as they harness their potential to live limitlessly and be ageless.

Each chapter represents the foundational codes to longevity that, when leveraged, allows the reader to be ageless. To unlock their code, Wright has included a complete longevity blueprint assessment. This will give readers an immediate action plan of the opportunities available for them to take so they can flourish and thrive to 120 and beyond.

The book is available for presale online at https://amzn.to/3gcGwEX. Wright's feature in Thriving Women Magazine can be read for free, online, at https://bit.ly/2VGCBag.

About Jill Wright

Jill is affectionately known as the Queen of shine. She is a heart centered leader and CEO of Executive Shine and has been recognized by both Forbes and Harvard business review for transforming the culture of client based services. As a thought leader and best selling author, she shares her 33 years of experience by speaking and consulting to inspire other leaders to unleash the human potential within their organizations through the power of belief and authentic connection. Get her free gift, 7 secrets to Authentic Human Connection at http://www.Theshinegift.com.

Media ContactCompany Name: Vedette Global MediaContact Person: Angel TuccyEmail: Send EmailPhone: 720-257-9293Country: United StatesWebsite: http://vedetteglobalmedia.com

The rest is here:
Bestselling Author, Jill Wright, Celebrates Feature in Thriving Women Magazine With Presale of Codes of Longevity - Press Release - Digital Journal

Recommendation and review posted by Alexandra Lee Anderson

As early as Tuesday, the coronavirus vaccine arrives. Who’s first in line, and what we know about who’s next – The Columbus Dispatch

Anne Saker|The Columbus Dispatch

With the scheduled Tuesdayarrival of dozens of dry-ice coolers, Ohiowill deploy a new defense against the novel coronavirus vials of vaccine invented, tested and put into service in record time. Here's what we know about who is in line for the vaccines, as well as their distribution and storage.

For at least the first three weeks of availability, the Ohio Department of Health has directed that only people to be vaccinated are:

All vaccination will be voluntary since the vaccines are still considered experimental.

>>Read More: With flu season off to mild start, experts say 'twindemic' is less likely but still possible

It's not clear yet the order of vaccination after Phase 1A. The states are waiting for the U.S. Centers for Disease Control and Prevention, which is developing the guidance, to recommend who is next,but the Ohio Department of Health has a draft plan that lists priorities.

Phase 1B would vaccinate older adults living in congregate or overcrowded settingsand people at significantly higher risk for COVID-19 because they have underlying health conditions.

>> This story is being provided free as a service to our readers during the coronavirus pandemic.You can find more stories on the coronavirus here.Please consider supporting local journalism with a subscription.

Phase 2 is where the jockeying comes in. This expansion of vaccination would include:

Critical risk workers essential to society (e.g., health care and public health operations and human services operations) and at high risk of exposure. This phase would also include:

Phase 3 would cover young adults, children, workers in essential industries and occupations not included in phases 1 and 2. Phase 4 is everyone else.

Because the initial quantities of the vaccines will be limited, public health officials urge maintaining vigilance about mask-wearing, hand-washing and social distancing. It could be at least a year before enough people are vaccinated to ease the health safeguards.

The clinical research has shown that the vaccine candidates do not generate severeside effects two months after the second injection. The shots might come with temporary side effects such as fever and muscle pain,a signal that the vaccine successfully triggered an immune reaction for the virus to be blocked.

CVS Pharmacy, Walgreens and two other private companies will be delivering and administering the vaccinations to nursing homes.

>>Read More: Ohio announces plans for initial COVID-19 vaccine distribution; DeWine tours warehouse

What we dont know: Whos precisely is next in line for the vaccine. Unions for grocery workers and other organizations for essential workers are jostling for the chance.

What we won't know for quite a while: How long immunity from the vaccine will last. The vaccineswere invented, put through clinical trials and brought to market inside a year. We don't have enough information about the longevity of theireffects.

Ohio COVID-19 vaccines: What to know about Pfizer vaccine distribution

Ohio is preparing to receive its first shipment of COVID-19 vaccines in the coming weeks. Here's what you need to know.

What we know: Right now, the Pfizer vaccine is expected to get emergency use authorization from the U.S. Food and Drug Administration at any moment and another one from Moderna is expected to be authorized in the next few weeks.But, public health agencies and hospitals, with long experience in planning vaccination campaigns, didn't wait for FDA approval to get ready. The delivery systemis set up and ready to receive the doses.

The two leading candidate vaccineseach pack slightly different pieces of genetic material from the virus. When injected, the messenger RNA makes the human immune system familiar enough with the virus to fight it off.

The vaccines dont prevent infection. But they stop it from progressing into the disease COVID-19, which has killed at least 290,000 Americans, including more than 7,200 Ohioans.

The vaccines are taken in two doses, like the two-shot series for shingles. The coronavirus vaccines, because they carry genetic material, require super-cold temperatures from the factory to distribution. The vials are packed in dry-ice coolers, a huge boost to Cold Jet based in the Cincinnati suburb of Loveland. For more than 30 years, the company has built dry-ice makers, and in 2020, sales have exploded more than 200% over 2019, said spokeswoman Lauren McNutt. Strong demand is expected well into 2021.

The vaccine manufacturers are the New York giant Pfizer working with the German company BioNTech and the Cambridge, Massachusetts-basedfirm Moderna. Both companies ran Cincinnati test sites for the final clinical trials and Pfizer enrolled test subjects in Columbus. AstraZeneca, which is working on another promising COVID-19 vaccine, enrolled trial participants at Ohio State University's Wexner Medical Center.

Last week, Gov. Mike DeWine announced the delivery schedule for Ohio.

On Tuesday, Pfizer delivers 9,750 doses to 10 Ohio hospitals, including Ohio State University Wexner Medical Center and OhioHealth Riverside Methodist Hospital,and 88,725 doses to Walgreens and CVS Pharmacy across the state, which will supply nursing homes.

On Dec. 22, Pfizer delivers another 123,000 doses for nursing homes and staff. Moderna delivers 201,000 doses to 98 hospitals for health care workers caring for COVID-19 patients and 108 health departments for emergency medical service workers and other first responders.

>>Read More: After decade-long fight for a new heart, central Ohio man sees COVID as his next test

The next week, the exactdate is not certain, Pfizer delivers another 148,000 doses and Moderna another 89,000 for workers and patients in hospitals and nursing homes.

What we dont know: These delivery totals are for the whole state. Its not clear yet how the shipments will be further divided for each of Ohios 88 counties, a decision that rests with the Ohio Department of Health.

Federal and state authorities have not released information on vaccine shipments past the end of December.

What we know: The cold chain doesnt stop at delivery. Pfizers vaccine candidate must be shipped and stored at minus 94.Once transferred to refrigeration to thaw for injection, it must be used within five days. Modernas candidate must be shipped and stored at minus 4 but can be stored for six months. Once in refrigeration, it keeps for up to 30 days.

Ohio hospital officials say they have the storage capacity for their doses of vaccine.

When the statedecides on how to apportion the doses as they arrive at county facilities, local public health officials from other jurisdictions can collect their shares.

Columbus Public Health has been preparing for the vaccine for months, said spokeswoman Kelli Newman. The city health department bough additional cold storage units in anticipation of the vaccine and the possibility of unique storage needs, Newman said.

"We have them in place and we are ready to go," Newman said."Once we receive the vaccine, we will be ready to distribute it strategically and equitably, beginning with those most at risk for COVID-19 complications and those working on the front lines during the pandemic."

Likewise, Franklin County Public Health has also beefed up its cold storage options for vaccines, said spokeswoman Mitzi Kline. The county health department hasordered one commercial grade refrigerator, two commercial grade freezers and several portable freezers, Kline said.

What we dont know: The location of the vaccine distribution warehouses isn't being disclosedto protect people, equipment and the doses.

Dispatch reporter Max Filby contributed to this story.

@apsaker

asaker@enquirer.com

Here is the original post:
As early as Tuesday, the coronavirus vaccine arrives. Who's first in line, and what we know about who's next - The Columbus Dispatch

Recommendation and review posted by Alexandra Lee Anderson

Jerry Seinfeld: Success is the enemy of irritability and crankiness how to stay productive and motivated – CNBC

It's been more than 20 years since Jerry Seinfeld's eponymous television show, which ran for nine seasons, ended. But Seinfeld, 66, still works as a comic and made $51 million dollars in 2020, according to Forbes.

So to what does Seinfeld credit his creativity and career longevity? "Having a very cranky nature," he said during a recent episode of the podcast, "The Tim Ferriss Show."

While Seinfeld may have been partially joking, he does have a process. Here the tips that keep Seinfeld motivated and you can use them, too.

Seinfeld said the majority of his job requires writing, editing and developing jokes, often re-writing every word in a joke several times on a legal pad until it feels perfect. Indeed, "work time" can be incredibly frustrating and occupying, he said.

But that's the same drive that keeps Seinfeld working: "Success is the enemy of irritability and crankiness," he said. "Because now you have money, and you can remove the difficulties from your life and that's not good."

As someone who has made a lot of money, Seinfeld said, "the thing that did that really solve almost all of that issue is I got married," he said. Being married and having kids means that the material will "never run out," he said.

"If you're going to write, make yourself a writing session," or a determine a digestible time that you're going to use to write or work on something, Seinfeld said. For example, you could set an alarm for 30 minutes or 10 minutes, depending upon what you feel like you can handle.

"Don't just sit down with an open ended," he said, "that's a ridiculous torture to put on a human being's head."

When you have an end point in sight, it also creates a reward to strive for, Steinfeld said on the podcast. "If you have the guts and the balls to sit down and write, you need a reward at the other end of that session," he said.

To stay organized, Seinfeld said he has two phases of writing: "the free, play, creative phase, and then there is the polish and construction phase." He often sits down with "15 or 20 pages of stuff that's in various stages of development," plus a smaller notebook with random notes and ideas, he said.

An idea "is like an archery target 50 yards away," he told Ferriss. "I take out my bow and my arrow, and I go, let me see if I can hit that." On a good day, he said he'll write about half a page of a legal pad.

Seinfeld likes to spend "inordinate amounts of time refining and perfecting every single word" until he's ready to share his material.

In fact, Seinfeld said he has a rule that he won't show people his writing right away. "I will always wait 24 hours before I say anything to anyone about what I wrote," he said. That way, he can enjoy the satisfaction of having written something, without another person's opinion getting in the way.

Check out:Barack Obama: I am not well organized 3 ways he stays productive

Don't miss:Amex Blue Cash Preferred is offering an elevated welcome bonus for a limited time

See the original post here:
Jerry Seinfeld: Success is the enemy of irritability and crankiness how to stay productive and motivated - CNBC

Recommendation and review posted by Alexandra Lee Anderson

Oxford Covid vaccine to be combined with Sputnik jab for trial – The Guardian

UK and Russian scientists are to test whether combining shots of the Oxford/AstraZeneca and Sputnik V coronavirus vaccines could result in better protection than two doses of the same one.

Trials will start by the end of the year, the Russian Direct Investment Fund (RDIF), which funded the development of the Sputnik V vaccine by Russias Gamaleya Institute, said on Friday. AstraZeneca confirmed that it was considering how it could assess combinations of different vaccines, and would soon begin exploring with the Gamaleya Institute whether their two vaccines could be successfully combined.

Like the Oxford/AstraZeneca vaccine, the Russian Sputnik V shot is based on a modified version of adenovirus, a common cold virus. This vector is stripped of any disease-causing genes and modified to carry genetic instructions for making the coronavirus spike protein, which it passes to human cells. The manufactured coronavirus spike protein then triggers an immune response that protects against the Covid-19 disease.

A potential problem with such vaccines, however, is that of anti-vector immunity, where if the immune system has previously encountered the type of adenovirus used in the vaccine, it may destroy it before the vaccine can trigger an immune response. This is why the Oxford University group chose to use a chimp adenovirus, rather than a human one. However, anti-vector immunity could also reduce the efficacy of booster shots, if this involves injecting the same virus for a second or third time.

Mixing and matching different vaccines may provide a solution. This concept is known as a heterologous prime-boost, and has been used in vaccination programmes against other diseases.

Now that the UK has authorised the first Covid vaccine, who will get it first?

The governments Joint Committee on Vaccination and Immunisation (JCVI) says its priority is to prevent Covid-related deaths and protect health and social care staff and systems.

Elderly care home residents and their carers are first on the JCVIs list because their risk of exposure to the virus is higher and because the risk of death closely correlates with older age. They are followed in priority by anyone else over 80 and frontline health and social care workers.

Even so, for pragmatic reasons NHS staff are likely to be the first group to receive the Pfizer/BioNTech jab. This is because the vaccine needs to be stored at ultra-cold temperatures, which can be achieved more easily by using hospital facilities

Are there enough doses to reach all the priority groups?

Together, care home residents, their carers and the over-80s make up nearly 6 million people, and frontline NHS staff a further 736,685. Matt Hancock, the health secretary, has said he expects 10m doses of the Pfizer/BioNTech vaccine to be available this year, so if this is the only vaccine authorised, everyone else would have to wait until further doses become available next year.

Where will I go for the vaccine?

Covid-19 vaccines are expected to be delivered at three types of venue: NHS trust vaccine hubs at hospital sites; mass vaccination centres, which are in the process of being set up at places such asfootball stadiums, conference buildingsand racecourses these are expected to vaccinate up to 5,000 people a day; and at GP surgeries and pharmacies. GPs can also visit care home residents and housebound patients at home without them needing to travel.

How far apart will the two doses be administered, and will I protected after the first?

While there is some evidence to indicate high levels of short-term protection from a single dose of vaccine, a two-dose schedule is what has been approved by theMHRA.

The second dose will need to be delivered at least 21 days after the first, and both will be injected into the deltoid muscle the thick triangular muscle we use to raise each arm.

For the Pfizer vaccine, its efficacy rate was calculated seven days after the second shot. It is likely that people will have some protection before this, but this is how long it will take for full protection to kick in. We will learn more about the extent of protection and how long it lasts as data from ongoing clinical trials comes in.

Can I pay to get the vaccine privately?

Unlikely. Englands deputy chief medical officer, Jonathan Van-Tam, has said he believes Covid-19 vaccines should be delivered according to clinical priority rather than allowing people to jump the queue if they can afford it.

Will I be able to choose which vaccine I have?

Also unlikely, at least in the short to medium term. Assuming more than one vaccine is approved, the priority will be distributing any available doses to the people who need it as quickly as possible.

Linda Geddes

Unlike AstraZenecas vaccine, Sputnik V uses two different human adenovirus vectors to try to trigger a stronger and longer-term immune response. It is not yet clear which of these components will be tested alongside the AstraZeneca vaccine.

Anti-vector immunity could also provide a possible explanation of why the AstraZeneca vaccine appears to work better when given as a half-dose followed by a full one, rather than two full doses.

Earlier this week, the outgoing chair of the UKs vaccine taskforce, Kate Bingham, announced that a trial of AstraZenecas vaccine in combination with the Pfizer shot was likely to begin in January. Its to do with trying to trigger the immune response and the durability [of the response], she said.

RDIF said it approached AstraZeneca about the possibility of combining its vaccines on 23 November.

This could eventually extend the duration of immunity and possibly also protect against people receiving the same vector repeatedly and having a less robust response, said Beate Kampmann, the director of the vaccine centre at the London School of Hygiene & Tropical Medicine. But for now these are all theoretical concepts that need to be carefully tested before they can be extended to population use.

Russia is likely to see the move as a vote of confidence by a western manufacturer in Sputnik V, which is already being used to immunise medical workers, teachers and social workers. Russian officials previously announced that the vaccine had more than 95% efficacy, giving it a success rate comparable to vaccines being developed by Pfizer and Moderna.

The decision by AstraZeneca to carry out clinical trials using one of two vectors of Sputnik V in order to increase its own vaccines efficacy is an important step towards uniting efforts in the fight against the pandemic, said Kirill Dmitriev, chief executive of RDIF. We hope that other vaccine producers will follow our example.

Dr Stephen Griffin, associate professor in the school of medicine, University of Leeds, said: The importance of a second jab should not be underestimated as it is important for the longevity, specificity and effectiveness of the response to most vaccines.

Visit link:
Oxford Covid vaccine to be combined with Sputnik jab for trial - The Guardian

Recommendation and review posted by Alexandra Lee Anderson

Stop the rain on human rights EURACTIV.com – EURACTIV

The current pandemic crisis serves as a magnifying glass of all existing inequalities in Europe racism, gender and sexual discrimination, treatment of migrants: there is still a long way to go to ensure full and real equality in Europe, write Helena Dalli and Dunja Mijatovi on the occasion of the Human Rights Day on 10 December.

Helena Dalli is the European Union Commissioner for Equality. Dunja Mijatovi is the Council of Europe Commissioner for Human Rights.

All human beings are born free and equal in dignity and rights. This very principle of equality enshrined in the Universal Declaration of Human Rights has inspired and transformed the lives of millions of Europeans and continues to give hope to countless more.

Regrettably, for all the progress of the past seven decades, there is still a long way to go to ensure full and real equality in Europe.

Our societies breed divisive levels of inequality, fear and polarisation. Structural discrimination keeps millions of Europeans on the margins of our societies, especially in employment, health, education, housing, and the criminal justice system.

The current pandemic crisis serves as a magnifying glass of all existing inequalities in Europe and exacerbates them. Those who were poor before it became poorer; those who were disadvantaged faced even greater disadvantages.

Inequalities affecting women, LGBTIQ people and ethnic minorities illustrate this problem well.

Although the situation varies from country to country, discriminatory treatment of women is ubiquitous. This is evident in the workplace, where deep-rooted societal attitudes contribute to maintaining the gender gap.

Violence against women and the obstacles faced by women in access to their sexual and reproductive health and rights also derive from ingrained patterns of inequalities between women and men.

Progress on ensuring equality for LGBTIQ people has been remarkable in some countries. However, in others the trend is worrying.

Restrictions to freedom of assembly and association, obstacles to legal gender recognition and lack of adequate protection at public events are evident failures of state authorities to uphold their commitments and legal human rights obligations to ensure equality for LGBTIQ people.

The situation is not much better for people from ethnic minority and immigrant backgrounds. If you are of African descent you are more likely than white people to face discrimination in the job market, in education and housing, and to be stopped by the police without reasonable suspicion.

Hate incidents also continue to scar the lives of Jews, Muslims and Roma, who are among the preferred scapegoats of those who still stigmatise some groups of people on the grounds of their ethnic origin or religion.

The unkept promise of equality betrays a long political, philosophical and judicial tradition which places equality at the centre of European democracies. Both the European Court of Justice and the European Court of Human Rights have upheld the principle of equality and non-discrimination since the 1970s.

Yet, more and more governments and parliaments seem to pay little attention to their legal obligations, and to the destabilising consequences that keeping millions of Europeans as second-class citizens is having on our societies.

Hard won progress longevity is not a given. We must protect and reinforce it every day.

The many challenges that our societies will have to face require that Europe strengthens the place equality occupies in our societies, starting by giving a more central focus to the principle of equality and non-discrimination in relations to all human rights, be they civil, political, economic social or cultural.

We must do better for the rights of the single mother living in poverty and for the disabled child prevented from attending a mainstream school. We must protect the rights of women and girls who have been sexually harassed, of young graduates who face discrimination in the labour market because of how their name sounds.

We also must remain vigilant in the face of worrying attempts to roll back progress towards equality for women and LGBTIQ people.

There is no easy fix, but already taking the decision to address these long-standing problems together is a good start. We firmly believe that the founding principles and values of the Universal Declaration are as relevant today as they were when they emerged from bloodshed, tyranny and war. They require that governments become stronger defenders of human rights.

We are helping them do so by addressing effectively the pervasive discriminations against women in Europe. Ratifying and implementing the Council of Europe Convention on preventing and combating violence against women and domestic violence is key to advance gender equality. This Convention has been ratified by 34 European countries, and signed by the EU.

However, the EU is not yet in a position to ratify because unanimity between member states has not been reached. We will join forces to make clear that the Convention protects from violence and nothing else; contrary to the misconceptions, fallacious and uninformed claims that have circulated and sown doubts.

Likewise, we are committed to fight racism and bring about an anti-racist culture. To this end, we believe that one of the priorities is to help member states stamp out ethnic profiling and end impunity for police misconduct.

We will also strengthen our work to counter discrimination against LGBTIQ people. We will continue to raise the visibility of LGBTIQ people in our dialogue with member states, support activists and use all means at our disposal to defend the right of LGBTIQ people to equality.

For this to happen, however, our voices alone will not suffice. There is the need for a renewed commitment by national authorities to uphold the founding values and legal obligations set out by the European Union and the Council of Europe. And here we get to the heart of the problem.

At best, many politicians in our member states remain indifferent about discrimination. At worst, they instigate violence and hostility. Politicians must be champions of equality, not obstacles to it. International organisations and the human rights community too have their bit to do.

We must become more inclusive in the way we defend human rights. We deliver a public service in the interest of society, but we do not own that service. We talk about, for and sometimes with people who have suffered human rights violations.

But we rarely empower them to speak for themselves. They should take part in decision-making processes as much as possible. We should learn to listen more and they must have the space to tell their stories and shape the policies and laws that concern them.

When states adopted the Universal Declaration on Human Rights on 10 December 1948, they pledged themselves to achieve equality. Giving practical effect to that vision is still possible but only if we choose to strengthen freedoms, promote participation and empower all people.

Originally posted here:
Stop the rain on human rights EURACTIV.com - EURACTIV

Recommendation and review posted by Alexandra Lee Anderson


Page 10«..9101112..2030..»